Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2025
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab ExposurePrerna Mewawalla, Rachel Dileo, Yue Yin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2014
Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosisBinod Dhakal, Christopher Strouse, Anita D'Souza, et al.
Cancer|May 20, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3Ajay K Nooka, Christopher Strouse, Sarah M Larson, et al.
Transplantation and Cellular Therapy|December 27, 2022
Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 StudySantosh Putta, Bradford A Young, John E Levine, et al.
Blood Cancer Journal|March 11, 2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myelomaRachel Dileo, Prerna Mewawalla, Kalaivani Babu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 22, 2018
Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell TransplantChristopher Strouse, Ying Zhang, Mei-Jie Zhang, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal ImpairmentAlma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
Cancers|November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed IntervalsJordan Snyder, Shebli Atrash, Barry Paul, et al.
Transplantation and Cellular Therapy|May 23, 2023
Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant CentersAkshay Sharma, Brent Logan, Noel Estrada-Merly, et al.
Pageof 4